#United States #Cleveland #GenomOncology #CNS Cancer #WeTrials

GenomOncology and WeTrials: A Game-Changing Collaboration

In a significant move to enhance clinical trial access for patients with central nervous system (CNS) cancer, GenomOncology, a frontrunner in precision medicine solutions, has announced a strategic partnership with WeTrials, an innovative platform that utilizes artificial intelligence to facilitate patient engagement and trial enrollment.

The Vision Behind the Collaboration

The core objective of this alliance is to empower CNS cancer patients by simplifying the process of accessing clinical trials. The integration of WeTrials into GenomOncology's system allows healthcare providers to guide patients more efficiently through potential trial options. This initiative is a substantial extension of their existing collaboration with Belay Diagnostics, which focuses on diagnosing CNS malignancies via advanced testing methodologies.

In recent months, Belay Diagnostics has successfully incorporated GenomOncology’s GO Pathology Workbench into its Summit™ 2.0 test, which leverages cerebrospinal fluid (CSF) to inform critical diagnostic insights. With this partnership, clinicians will now have direct access from genomic reports to the WeTrials platform, making the transition from diagnosis to trial enrollment smoother than before.

Streamlining the Enrollment Process

Dr. Alireza Mansouri, co-founder and Chief Medical Officer of WeTrials, emphasizes the importance of this integration: “Clinical trials should be a primary consideration, not a last resort. This partnership enables physicians and patients to navigate trial options seamlessly, significantly reducing barriers to enrollment.” The ability to click directly from a genomic report to a user-friendly trial information page enhances patient awareness and opportunities to participate in relevant studies.

Dr. Honey Reddi, Chief Laboratory Officer at Belay Diagnostics, shares a similar sentiment, stating that the collaboration directly puts essential resources in the hands of clinicians. “When patients receive test results that indicate potential clinical trial avenues, they should be able to pursue these options without delay,” she remarks, highlighting the streamlined approach this partnership aims to achieve.

A Collaborative Effort Towards Impactful Change

Garreth Hippe, Chief Commercial Officer at GenomOncology, remarks, “Our genomic reports must lead to actionable outcomes. By integrating WeTrials directly into our reports, we make enrollment support accessible without complicating workflows. This initiative truly prioritizes patient needs.” The current phase of this partnership is primarily directed toward CNS cancer patients who utilize Belay Diagnostics’ services, but there are plans to expand this initiative to encompass other diagnostic partners and various cancer forms in the future.

As the healthcare community increasingly realizes the critical role of clinical trials in advancing cancer treatment, partnerships like these illuminate a promising path forward. Patients now stand to benefit from a more efficient enrollment process, backed by cutting-edge technology and collaborative expertise.

About the Companies Involved

GenomOncology is dedicated to transforming complex clinical data into actionable insights for precision cancer care. Their solutions focus on enhancing clinical genomic reporting and optimizing trial opportunities seamlessly within existing workflows, providing invaluable support for patient treatment decisions.

WeTrials operates as an AI-driven patient engagement platform, making it easier for patients and medical professionals to navigate clinical trial landscapes through clear, accessible information. Their approach seeks to accelerate trial awareness, access, and enrollment, fundamentally rethinking how clinical trials are approached.

Belay Diagnostics aims to deliver insightful diagnostic solutions, utilizing liquid biopsy tests that inform both diagnosis and treatment options for CNS malignancies. Their commitment is to improve patient care by providing essential data that supports clinical decision-making.

This new collaboration is set to reshape how CNS cancer patients engage with potentially life-saving clinical trials, marking a significant step forward in the realm of precision medicine.